BlackRock Inc. lifted its position in VIVUS, Inc. (NASDAQ:VVUS) by 6.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 220,707 shares of the biopharmaceutical company’s stock after purchasing an additional 13,572 shares during the period. BlackRock Inc.’s holdings in VIVUS were worth $843,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Shares of NASDAQ VVUS opened at $3.83 on Tuesday. The firm has a fifty day moving average price of $3.98 and a 200-day moving average price of $3.73. The stock has a market cap of $40.87 million, a PE ratio of -1.10 and a beta of 1.78. VIVUS, Inc. has a 1 year low of $2.15 and a 1 year high of $5.78.
VIVUS (NASDAQ:VVUS) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.00) by $0.44. The firm had revenue of $18.39 million during the quarter, compared to analysts’ expectations of $16.88 million. On average, sell-side analysts expect that VIVUS, Inc. will post -2.44 earnings per share for the current fiscal year.
Separately, ValuEngine cut shares of VIVUS from a “hold” rating to a “sell” rating in a research note on Monday, October 21st.
VIVUS Company Profile
VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol.
Further Reading: How is inflation measured?
Want to see what other hedge funds are holding VVUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VIVUS, Inc. (NASDAQ:VVUS).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.